Helping You Build Wealth With Honest Research
Since 1996. Read On...

The Best Asset Allocation for Your Equity Portfolio

GLENMARK LIFE SCIENCES Gains 5%; BSE HEALTHCARE Index Down 1.2%
Wed, 15 Jan 15:7

GLENMARK LIFE SCIENCES Gains 5%; BSE HEALTHCARE Index Down 1.2%Image source: StarLineArts/www.istockphoto.com

GLENMARK LIFE SCIENCES share price has zoomed 5% and is presently trading at Rs 1,065.6.

Meanwhile, the BSE HEALTHCARE index is at 42,510.9 (down 1.2%).

Among the top gainers in the BSE HEALTHCARE index today are Procter & Gamble Health (up 3.0%) and ERIS LIFESCIENCES (up 1.9%).

CAPLIN POINT (down 4.5%) and MAX HEALTHCARE INSTITUTE (down 4.4%) are among the top losers today.

Over the last one year, GLENMARK LIFE SCIENCES has moved up from Rs 747.9 to Rs 1,065.6, registering a gain of Rs 317.7 (up 42.5%).

On the other hand, the BSE HEALTHCARE index has moved up from 32,835.5 to 42,510.9, registering a gain of 29.5% during the last 12 months.

The top gainers among the BSE HEALTHCARE index stocks during this same period were POLY MEDICURE (up 72.5%), Jubilant Pharmova (up 69.0%) and Glenmark Pharma (up 62.2%).

Time Sensitive: Access Our 4 Foundational Stock Recommendation Services at 75% OFF

What About the Benchmark Indices?

The BSE Sensex is at 76,741.3 (up 0.3%).

The top gainers among the BSE Sensex today are ZOMATO (up 3.8%) and NTPC (up 3.1%). The most traded stocks in the BSE Sensex are Axis Bank and ZOMATO.

In the meantime, NSE Nifty is at 23,211.2 (up 0.2%). Trent and NTPC are among the top gainers in NSE NIFTY.

Over the last 12 months, the BSE Sensex has moved up from 73,327.9 to 76,741.3, registering a gain of 3,413.4 points (up 4.7%).

GLENMARK LIFE SCIENCES Financial Update...

GLENMARK LIFE SCIENCES net profit fell 19.7% YoY to Rs 953 million for the quarter ended September 2024, compared to a profit of Rs 1,187 million a year ago. Net sales declined 14.9% to Rs 5,069 million during the period as against Rs 5,954 million in July-September 2023.

For the year ended March 2024, GLENMARK LIFE SCIENCES reported 0.8% increase in net profit to Rs 4,709 million compared to net profit of Rs 4,670 million during FY23. Revenue of the company grew 5.6% to Rs 22,832 million during FY24.

The current Price to earnings ratio of GLENMARK LIFE SCIENCES, based on rolling 12 month earnings, stands at 30.8.


Equitymaster requests your view! Post a comment on "GLENMARK LIFE SCIENCES Gains 5%; BSE HEALTHCARE Index Down 1.2%". Click here!